Clinical Trial

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-15.
Trial Details
NCT Number NCT07035405
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Shenzhen Medical Academy of Research and Translation
Conditions Stroke
Enrollment 7,500 participants
Start Date 2025-07-04
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-27